{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:05:14Z","timestamp":1780553114882,"version":"3.54.1"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The COVID-19 pandemic established mRNA vaccines as a clinically validated platform for rapid vaccine development and deployment. This review summarizes recent progress in COVID-19 mRNA vaccine technology, clinical performance, immunological mechanisms, and translational applications. First-generation nucleoside-modified mRNA vaccines formulated in lipid nanoparticles demonstrated strong protection against symptomatic disease and, more durably, against severe outcomes, while variant-driven immune escape, waning protection against infection, limited mucosal immunity, and heterogeneous responses in special populations revealed important constraints. The review compares mRNA vaccines with other COVID-19 vaccine platforms and clarifies endpoint-specific correlates of protection, emphasizing the distinct roles of neutralizing antibodies, memory B cells, T-cell responses, and non-neutralizing antibody functions. It further examines unresolved issues associated with repeated vaccination, including immune imprinting and IgG4 class switching, and evaluates technological strategies designed to improve durability, breadth, delivery, and immune programming. Key innovations include optimized RNA chemistry, structure-guided antigen design, advanced lipid nanoparticle formulations, alternative delivery systems, immune-shaping adjuvant approaches, and next-generation RNA formats such as self-amplifying RNA and circular RNA. Finally, the review discusses vaccination strategies for immunocompromised individuals, pregnant and lactating women, older adults, and children, as well as the expansion of mRNA technology into respiratory virus vaccines, cancer immunotherapy, and therapeutic protein expression. These developments define mRNA technology as a modular platform whose clinical impact depends on aligning RNA architecture, delivery system, antigen design, and target population.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1757291","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:43:30Z","timestamp":1780551810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 mRNA vaccines: a prospective outlook from technological innovation to clinical practice"],"prefix":"10.3389","volume":"17","author":[{"given":"Junqi","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Genetics and Precision Medicine Laboratory, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huoying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Guangxi Key Laboratory of Multimodal Biomarkers and Precision Diagnosis, Guilin Medical University","place":["Guilin, Guangxi, China"]},{"name":"School of Laboratory Medicine and Biotechnology, Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"He","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Biotechnology, Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Genetics and Precision Medicine Laboratory, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlong","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Genetics and Precision Medicine Laboratory, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiliang","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Biotechnology, Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangxi Key Laboratory of Multimodal Biomarkers and Precision Diagnosis, Guilin Medical University","place":["Guilin, Guangxi, China"]},{"name":"School of Laboratory Medicine and Biotechnology, Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University","place":["Guilin, China"]},{"name":"Genetics and Precision Medicine Laboratory, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]},{"name":"Guangxi Key Laboratory of Multimodal Biomarkers and Precision Diagnosis, Guilin Medical University","place":["Guilin, Guangxi, China"]},{"name":"School of Laboratory Medicine and Biotechnology, Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-024-6978-6","article-title":"mRNA medicine: Recent progresses in chemical modification, design, and engineering","volume":"17","author":"Hou","year":"2024","journal-title":"Nano Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.034","article-title":"Clinical development of therapeutic mRNA applications","volume":"33","author":"\u017bak","year":"2025","journal-title":"Mol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217752","article-title":"Cancer mRNA vaccines: clinical application progress and challenges","volume":"625","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3003114","article-title":"Priorities for rapid and cost-effective vaccines to improve outbreak responses","volume":"23","author":"Gilbert","year":"2025","journal-title":"PloS Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2471035","article-title":"Lessons for medical countermeasure development from unforeseen outbreaks","volume":"14","author":"Mura","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1038\/s41467-025-60024-9","article-title":"Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08910-6","article-title":"Nasal vaccines for respiratory infections","volume":"641","author":"Kiyono","year":"2025","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp8920","article-title":"SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity","volume":"16","author":"Lasrado","year":"2024","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"240222","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur Respir Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.17402","article-title":"Estimated 2023-2024 COVID-19 vaccine effectiveness in adults","volume":"8","author":"Link-Gelles","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-001074","article-title":"Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data","volume":"3","author":"Andersson","year":"2024","journal-title":"BMJ Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00380-9","article-title":"Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study","volume":"25","author":"Hansen","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-coV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance - eight U.S. Locations, december 2020-august 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01015","article-title":"Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 vaccines over long-term follow-up : A target trial emulation","volume":"178","author":"Ioannou","year":"2025","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","article-title":"Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare system","volume":"15","author":"Caffrey","year":"2024","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00101-1","article-title":"Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study","volume":"10","author":"Tartof","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00306-5","article-title":"Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2428800","article-title":"Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86\/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study","volume":"23","author":"Nunes","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B25","unstructured":"COVID-19 vaccine effectiveness update CDC ACIP slides\n          \n          \n            \n              Srinivasan\n            \n          \n          \n          2025"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.02.026","article-title":"Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4\/BA.5 mRNA booster","volume":"155","author":"Wachter","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1038\/s41467-024-54404-w","article-title":"Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection","volume":"15","author":"Wiegand","year":"2024","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12916-025-04211-x","article-title":"Dynamics of contact behaviour by self-reported COVID-19 vaccination and infection status during the COVID-19 pandemic in Germany: an analysis of two large population-based studies","volume":"23","author":"Boff","year":"2025","journal-title":"BMC Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1038\/s41467-025-59768-1","article-title":"Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study","volume":"16","author":"Bodner","year":"2025","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.12763","article-title":"Evaluating the test-negative design for COVID-19 vaccine effectiveness using randomized trial data: A secondary cross-protocol analysis of 5 randomized clinical trials","volume":"8","author":"Andrews","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5646","article-title":"Immunogenicity and safety of influenza and COVID-19 multicomponent vaccine in adults >\/=50 years: A randomized clinical trial","volume":"333","author":"Rudman Spergel","year":"2025","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-publhealth-071723-102841","article-title":"Adverse events following vaccines: from detection to research translation","volume":"46","author":"Fernandez","year":"2025","journal-title":"Annu Rev Public Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1038\/s41467-025-61613-4","article-title":"Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study","volume":"16","author":"Pan","year":"2025","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.23557","article-title":"Safety of JN.1-updated mRNA COVID-19 vaccines","volume":"8","author":"Andersson","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-025-00612-6","article-title":"The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after SARS-CoV-2 infection and COVID-19 vaccination","volume":"4","author":"Maatz","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae639","article-title":"Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study","volume":"46","author":"Xu","year":"2025","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.16380","article-title":"Long-term prognosis of patients with myocarditis attributed to COVID-19 mRNA vaccination, SARS-coV-2 infection, or conventional etiologies","volume":"332","author":"Semenzato","year":"2024","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.12.070","article-title":"Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study","volume":"42","author":"Shenton","year":"2024","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.23688","article-title":"Cost-effectiveness of 2023-2024 COVID-19 vaccination in US adults","volume":"8","author":"Prosser","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15534","article-title":"Cost-utility analysis of COVID-19 vaccination strategies for endemic SARS-coV-2","volume":"8","author":"Miranda","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.2223","article-title":"Global estimates of lives and life-years saved by COVID-19 vaccination during 2020-2024","volume":"6","author":"Ioannidis","year":"2025","journal-title":"JAMA Health Forum"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00286-9","article-title":"Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study","volume":"12","author":"Barnsley","year":"2024","journal-title":"Lancet Glob Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2459140","article-title":"In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models","volume":"14","author":"Wei","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-025-02319-3","article-title":"Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024","volume":"10","author":"He","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12916-025-04157-0","article-title":"Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study","volume":"23","author":"Kwesi-Maliepaard","year":"2025","journal-title":"BMC Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08511-9","article-title":"Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron","volume":"639","author":"Chemaitelly","year":"2025","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105461","article-title":"Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants","volume":"110","author":"Shrestha","year":"2024","journal-title":"EBioMedicine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116142","article-title":"Clonal expansion and diversification of germinal center and memory B cell responses to booster immunization in primates","volume":"44","author":"Deimel","year":"2025","journal-title":"Cell Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.08.008","article-title":"mRNA prime-boost vaccination promotes clonal continuity in germinal center reactions and broadens SARS-CoV-2 variant coverage","volume":"33","author":"Ciancaglini","year":"2025","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115557","article-title":"Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection","volume":"44","author":"Kardava","year":"2025","journal-title":"Cell Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115907","article-title":"Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters","volume":"44","author":"da Silva Antunes","year":"2025","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1038\/s41467-025-60216-3","article-title":"No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations","volume":"16","author":"Benoit","year":"2025","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105809","article-title":"Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial","volume":"117","author":"Hertoghs","year":"2025","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114922","article-title":"Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination","volume":"43","author":"Clark","year":"2024","journal-title":"Cell Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01970-2","article-title":"Vaccination against rapidly evolving pathogens and the entanglements of memory","volume":"25","author":"Cobey","year":"2024","journal-title":"Nat Immunol"},{"key":"B62","article-title":"On the doctrine of original antigenic sin","volume":"104","author":"Francis","year":"1960","journal-title":"Proc Am Philos Soc"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02162-2","article-title":"Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections","volume":"26","author":"Quirk","year":"2025","journal-title":"Nat Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2412623","article-title":"Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine","volume":"13","author":"Yisimayi","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70273","article-title":"Leveraged vaccination to alleviate original antigenic sin for enhancing broad-neutralizing antibody response against SARS-CoV-2 Omicron subvariants","volume":"6","author":"Zhang","year":"2025","journal-title":"MedComm (2020)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115964","article-title":"A rare B cell clonotype imprinted by ancestral SARS-CoV-2 develops cross-sarbecovirus neutralization in immune recalls","volume":"44","author":"Chen","year":"2025","journal-title":"Cell Rep"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101103","article-title":"Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis","volume":"6","author":"Fantin","year":"2025","journal-title":"Lancet Microbe"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116000","article-title":"Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses","volume":"44","author":"Tam","year":"2025","journal-title":"Cell Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads1482","article-title":"Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant","volume":"11","author":"Aurelia","year":"2025","journal-title":"Sci Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ads6271","article-title":"From blood to mucosa","volume":"16","author":"Tang","year":"2024","journal-title":"Sci Transl Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1038\/s41467-025-62698-7","article-title":"Safety and immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial","volume":"16","author":"Wu","year":"2025","journal-title":"Nat Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2506821122","article-title":"Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission","volume":"122","author":"Hsu","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B75","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1038\/s41467-025-60726-0","article-title":"Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial","volume":"16","author":"Jeyanathan","year":"2025","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.007","article-title":"Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission","volume":"33","author":"Jennewein","year":"2025","journal-title":"Mol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105615","article-title":"Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection","volume":"113","author":"Worzner","year":"2025","journal-title":"EBioMedicine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41392-024-02025-6","article-title":"Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants","volume":"9","author":"Lei","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"8355","DOI":"10.1038\/s41467-024-52689-5","article-title":"SARS-CoV-2 spike-specific nasal-resident CD49a(+)CD8(+) memory T cells exert immediate effector functions with enhanced IFN-gamma production","volume":"15","author":"Rha","year":"2024","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113891","article-title":"Chitosan and mannose-modified dual-functional mRNA-LNP vaccines for robust systemic and mucosal immune responses","volume":"384","author":"Yi","year":"2025","journal-title":"J Control Release"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407383","article-title":"Muco-penetrating lipid nanoparticles having a liquid core for enhanced intranasal mRNA delivery","volume":"12","author":"Maniyamgama","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B82","doi-asserted-by":"publisher","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02156-0","article-title":"Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice","volume":"26","author":"Kwon","year":"2025","journal-title":"Nat Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e175233","DOI":"10.1172\/JCI175233","article-title":"Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2","volume":"135","author":"Lin","year":"2025","journal-title":"J Clin Invest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.10.016","article-title":"Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant","volume":"32","author":"Laghlali","year":"2024","journal-title":"Mol Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41580-025-00852-1","article-title":"Functions and therapeutic applications of pseudouridylation","volume":"26","author":"Luo","year":"2025","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08842-1","article-title":"Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines","volume":"641","author":"Krawczyk","year":"2025","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn5651","article-title":"Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates","volume":"17","author":"Malewana","year":"2025","journal-title":"Sci Transl Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.5c05367","article-title":"Breaking endosomal barriers: thiol-mediated uptake lipid nanoparticles for efficient mRNA vaccine delivery","volume":"147","author":"Lian","year":"2025","journal-title":"J Am Chem Soc"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70035","article-title":"Nonviral targeted mRNA delivery: principles, progresses, and challenges","volume":"6","author":"He","year":"2025","journal-title":"MedComm (2020)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.01.071","article-title":"Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines","volume":"380","author":"Zhang","year":"2025","journal-title":"J Control Release"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123421","article-title":"Cost-effective yet high-performance ionizable lipids for mRNA-lipid nanoparticle vaccines","volume":"323","author":"Gao","year":"2025","journal-title":"Biomaterials"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01267-7","article-title":"Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution","volume":"8","author":"Han","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B97","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jconrel.2024.10.028","article-title":"Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo","volume":"376","author":"Wu","year":"2024","journal-title":"J Control Release"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.5c00088","article-title":"Replacing PEG-lipid with amphiphilic polycarbonates in mRNA-loaded lipid nanoparticles: impact of polycarbonate structure on physicochemical and transfection properties","volume":"26","author":"Le","year":"2025","journal-title":"Biomacromolecules"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113821","article-title":"Impact of pre-existing anti-polyethylene glycol (PEG) IgM on biodistribution and humoral response of intramuscularly administered PEGylated mRNA loaded lipid nanoparticle","volume":"383","author":"Abe","year":"2025","journal-title":"J Control Release"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.11.007","article-title":"Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity","volume":"376","author":"Wu","year":"2024","journal-title":"J Control Release"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr2631","article-title":"Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines","volume":"11","author":"Meany","year":"2025","journal-title":"Sci Adv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.12.054","article-title":"Controlling vaccine kinetics using tannic acid for enhanced humoral immunity","volume":"379","author":"Janes","year":"2025","journal-title":"J Control Release"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.08.005","article-title":"Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells","volume":"204","author":"Zhou","year":"2025","journal-title":"Acta Biomater"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412116","article-title":"Spatiotemporal dynamic immunomodulation by infection-mimicking gels enhances broad and durable protective immunity against heterologous viruses","volume":"12","author":"Jin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41563-024-02115-4","article-title":"On-patient medical record and mRNA therapeutics using intradermal microneedles","volume":"24","author":"Han","year":"2025","journal-title":"Nat Mater"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.01.069","article-title":"Microneedle-delivered adeno-associated virus vaccine amplified anti-viral immunity by improving antigen-presenting cells infection","volume":"379","author":"He","year":"2025","journal-title":"J Control Release"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01306-6","article-title":"Multiscale dynamic immunomodulation by a nanoemulsified Trojan-TLR7\/8 adjuvant for robust protection against heterologous pandemic and endemic viruses","volume":"22","author":"Yoo","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1038\/s41467-025-58006-y","article-title":"Kinetically activating nanovaccine mimicking multidimensional immunomodulation of natural infection for broad protection against heterologous viruses in animal models","volume":"16","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1186\/s12951-024-02993-5","article-title":"IL-7 promotes mRNA vaccine-induced long-term immunity","volume":"22","author":"Wang","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202412654","article-title":"STING-activating polymers boost lymphatic delivery of mRNA vaccine to potentiate cancer immunotherapy","volume":"37","author":"Zhang","year":"2025","journal-title":"Adv Mater"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT183","article-title":"Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients with advanced solid tumors","volume":"82","author":"Carneiro","year":"2022","journal-title":"Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","first-page":"A569","DOI":"10.1136\/jitc-2021-SITC2021.539","article-title":"Abstract 539: Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral injection with or without durvalumab in advanced solid tumors and lymphoma","volume":"9","author":"Patel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9556","article-title":"Abstract 9556: Phase I dose-escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients with advanced solid tumors","volume":"43","author":"Piha-Paul","year":"2025","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S1473-3099(24)00565-6","article-title":"Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4\/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4\/5 mRNA vaccine: a randomised phase 3 trial","volume":"25","author":"Okada","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1038\/s41467-024-47905-1","article-title":"Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials","volume":"15","author":"H\u1ed3","year":"2024","journal-title":"Nat Commun"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00615-7","article-title":"12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B119","volume-title":"Kostaive","year":"2025"},{"key":"B120","volume-title":"Meiji Seika Pharma receives manufacturing and marketing approval of \u201cARCT-154\u201d, self-amplifying mRNA vaccine against COVID-19, from MHLW in Japan","year":"2023"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02955-2","article-title":"An omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat Med"},{"key":"B122","volume-title":"Safety and immunogenicity of HDT-301 targeting a SARS-coV-2 variant spike protein (NCT05132907)","year":"2024"},{"key":"B123","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat Commun"},{"key":"B124","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s43856-025-01147-4","article-title":"Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial","volume":"5","author":"Maine","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.055","article-title":"Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-022-00435-8","article-title":"Next generation self-replicating RNA vectors for vaccines and immunotherapies","volume":"30","author":"Aliahmad","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"S1525-0016(26)00212-1","DOI":"10.1016\/j.ymthe.2026.03.026","article-title":"Enhanced efficacy of a next-generation EEEV self-replicating RNA platform for combination cancer immunotherapies","author":"Miyake-Stoner","year":"2026","journal-title":"Mol Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98214","article-title":"Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00236-1","article-title":"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial","volume":"25","author":"Chalkias","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.12.015","article-title":"Designed mosaic nanoparticles enhance cross-reactive immune responses in mice","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c06081","article-title":"Lumazine synthase nanoparticles as a versatile platform for multivalent antigen presentation and cross-protective coronavirus vaccines","volume":"19","author":"Joseph","year":"2025","journal-title":"ACS Nano"},{"key":"B132","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41467-025-55824-y","article-title":"Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice","volume":"16","author":"Halfmann","year":"2025","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12951-025-03582-w","article-title":"Targeting heptad repeats and fusion peptide: nanoparticle vaccine elicits mucosal immune response against SARS-CoV-2 variants","volume":"23","author":"Liang","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409919","article-title":"Pan-variant SARS-CoV-2 vaccines induce protective immunity by targeting conserved epitopes","volume":"12","author":"Shah","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102050","article-title":"Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients","volume":"6","author":"Hu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105577","article-title":"Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of omicron-adapted booster doses","volume":"113","author":"Ciabattini","year":"2025","journal-title":"EBioMedicine"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115838","article-title":"Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors","volume":"44","author":"Ravera","year":"2025","journal-title":"Cell Rep"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq3342","article-title":"Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression","volume":"11","author":"Kamelian","year":"2025","journal-title":"Sci Adv"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e192589","DOI":"10.1172\/JCI192589","article-title":"Reduced vaccine-induced germinal center outputs in patients with inflammatory bowel disease treated with anti-TNF biologics","volume":"135","author":"Cheung","year":"2025","journal-title":"J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105620","article-title":"Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment","volume":"113","author":"Keijser","year":"2025","journal-title":"EBioMedicine"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02560-1","article-title":"Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study","volume":"405","author":"Mumford","year":"2025","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.11.033","article-title":"Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients","volume":"25","author":"Azarfar","year":"2025","journal-title":"Am J Transplant"},{"key":"B144","volume-title":"IDSA guidelines on vaccination for immunocompromised patients","year":"2025"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101025","article-title":"COVID-19 vaccination and birth outcomes of 186,990 women vaccinated before pregnancy: an England-wide cohort study","volume":"45","author":"Suseeladevi","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.3456","article-title":"Peripartum outcomes associated with COVID-19 vaccination during pregnancy: a systematic review and meta-analysis","volume":"176","author":"Watanabe","year":"2022","journal-title":"JAMA Pediatr"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00689","article-title":"Sins of omission: model-based estimates of the health effects of excluding pregnant participants from randomized controlled trials","volume":"178","author":"Bilinski","year":"2025","journal-title":"Ann Intern Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(25)00008-2","article-title":"Early childhood developmental concerns following SARS-CoV-2 infection and COVID-19 vaccination during pregnancy: a Scottish population-level retrospective cohort study","volume":"9","author":"Hardie","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.191930","article-title":"Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infection","volume":"10","author":"Yin","year":"2025","journal-title":"JCI Insight"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103439","article-title":"Passive maternal immunity in children born to women with systemic autoimmune rheumatic disease - a case-control study","volume":"154","author":"Mazzucato-Puchner","year":"2025","journal-title":"J Autoimmun"},{"key":"B151","volume-title":"COVID-19 vaccines while pregnant or breastfeeding","year":"2025"},{"key":"B152","volume-title":"Drugs and lactation database (LactMed\u00ae)","year":"2025"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.100646","article-title":"Global landscape of COVID-19 vaccination programmes for older adults: a descriptive study","volume":"5","author":"Zheng","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"B154","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12916-025-04171-2","article-title":"SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023","volume":"23","author":"Sarjomaa","year":"2025","journal-title":"BMC Med"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e183913","DOI":"10.1172\/jci.insight.183913","article-title":"Antibody levels versus vaccination status in the outcome of older adults with COVID-19","volume":"9","author":"Mink","year":"2024","journal-title":"JCI Insight"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115314","article-title":"Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly","volume":"44","author":"Loyal","year":"2025","journal-title":"Cell Rep"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.012","article-title":"Coronavirus disease 2019 (COVID-19) in children: Evolving epidemiology, immunology, symptoms, diagnostics, treatment, post-COVID-19 conditions, prevention strategies, and future directions","volume":"155","author":"Wurm","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59672","article-title":"COVID-19 vaccination and odds of post-COVID-19 condition symptoms in children aged 5 to 17 years","volume":"8","author":"Yousaf","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2436714","article-title":"Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents","volume":"21","author":"Figueroa","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-024-02097-y","article-title":"Healthcare use in 12-18-year-old adolescents vaccinated against SARS-CoV-2 versus unvaccinated in a national register-based Danish cohort","volume":"9","author":"Berg","year":"2025","journal-title":"Nat Hum Behav"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49944","article-title":"BNT162b2 XBB vaccine for COVID-19 among children 5-17 years of age","volume":"7","author":"Tartof","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"B163","volume-title":"MRESVIA","year":"2024"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J BioMed Sci"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401287","article-title":"A universal strategy of anti-tumor mRNA vaccine by harnessing \"off-the-shelf\" immunity","volume":"12","author":"Fu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028597","article-title":"A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma","volume":"146","author":"Dutta","year":"2025","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c15187","article-title":"Self-assembled glycopeptide as a biocompatible mRNA vaccine platform elicits robust antitumor immunity","volume":"19","author":"Zhou","year":"2025","journal-title":"ACS Nano"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ads1273","article-title":"An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus","volume":"16","author":"Hatta","year":"2024","journal-title":"Sci Transl Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03591-0","article-title":"mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1\/2 trial","volume":"31","author":"Rudman Spergel","year":"2025","journal-title":"Nat Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adt9576","article-title":"Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice","volume":"17","author":"Zhang","year":"2025","journal-title":"Sci Transl Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02701","article-title":"High frequency of chronic urticaria following an investigational HIV-1 BG505 MD39.3 trimer mRNA vaccine in a phase 1, randomized, open-label clinical trial (HVTN 302)","volume":"178","author":"Riddler","year":"2025","journal-title":"Ann Intern Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01889-1","article-title":"A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25","volume":"20","author":"Fougeroux","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e187405","DOI":"10.1172\/jci.insight.187405","article-title":"Enhanced durability of a Zika virus self-amplifying RNA vaccine through combinatorial OX40 and 4-1BB agonism","volume":"10","author":"Lu","year":"2025","journal-title":"JCI Insight"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113837","article-title":"Unlock the sustained therapeutic efficacy of mRNA","volume":"383","author":"Cao","year":"2025","journal-title":"J Control Release"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7107e2","article-title":"Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19\u2013associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance \u2014 VISION Network, 10 States, August 2021\u2013January 2022","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215471","article-title":"Effectiveness of bivalent boosters against severe Omicron infection","volume":"388","author":"Lin","year":"2023","journal-title":"N Engl J Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae370","article-title":"Effectiveness of BNT162b2 XBB vaccine against XBB and JN.1 sublineages","volume":"11","author":"Tartof","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113944","article-title":"Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle array patch delivery","volume":"384","author":"Driskill","year":"2025","journal-title":"J Control Release"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757291\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:43:36Z","timestamp":1780551816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1757291\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":182,"alternative-id":["10.3389\/fimmu.2026.1757291"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1757291","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1757291"}}